Brii Biosciences Report issue

For profit Phase 2 Phase 3
Founded: San Francisco CA United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04479631
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Brii Biosciences, Inc. | Brii Biosciences Limited

Active Ingredients

Drugs in Phase 3 Trials (5)

brii-196 (5 trials)

brii-198 (5 trials)

ly3819253 (1 trial)

remdesivir (1 trial)

vir-7831 (1 trial)

Drugs in Phase 2 Trials (3)

brii-179 (1 trial)

interferon alfa-1b (1 trial)

vir-2218 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 8